{
  "pmcid": "1283103",
  "sha256": "fa1faba97867673bee65eb74bf0fcb43f10a6c2de61a8ec308c387fffe733ccb",
  "timestamp_utc": "2025-11-09T23:43:09.530173+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.082688534641328,
    "reading_ease": 30.909023605150225,
    "word_count": 233
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Ketamine and Nefopam for Potentiating Opioid Analgesia"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "200 participants were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at [Study Setting], this randomised controlled trial included adults eligible for opioid analgesia."
      },
      "Intervention": {
        "score": 2,
        "evidence": "100 to receive ketamine 10 mg and 100 to receive nefopam 20 mg."
      },
      "Objective": {
        "score": 1,
        "evidence": "The objective of this study was to evaluate the efficacy and safety of ketamine and nefopam in enhancing opioid analgesia."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the reduction in opioid requirement over a 24-hour period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding was maintained for patients and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 200 participants were randomised: 100 to receive ketamine 10 mg and 100 to receive nefopam 20 mg."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "An intention-to-treat analysis was performed."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Both ketamine and nefopam reduced opioid requirements by approximately 40% (mean difference = [value], 95% CI [range]; p = [value])."
      },
      "Harms": {
        "score": 1,
        "evidence": "In the ketamine group, sedation was reported, while the nefopam group experienced tachycardia and sweating."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 1,
        "evidence": "This study was supported by [Funding Source]."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}